JP7279054B2 - Ｅｄｂ標的化ｉｌ－１２組成物 - Google Patents

Ｅｄｂ標的化ｉｌ－１２組成物 Download PDF

Info

Publication number
JP7279054B2
JP7279054B2 JP2020542822A JP2020542822A JP7279054B2 JP 7279054 B2 JP7279054 B2 JP 7279054B2 JP 2020542822 A JP2020542822 A JP 2020542822A JP 2020542822 A JP2020542822 A JP 2020542822A JP 7279054 B2 JP7279054 B2 JP 7279054B2
Authority
JP
Japan
Prior art keywords
linker
domain
protein
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542822A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019154986A5 (https=
JP2021513536A (ja
JP2021513536A5 (https=
Inventor
アレッサンドラ ヴィッラ
マッティア マタシ
ティツィアーノ オンガーロ
Original Assignee
フィロジェン ソチエタ ペル アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィロジェン ソチエタ ペル アツィオーニ filed Critical フィロジェン ソチエタ ペル アツィオーニ
Publication of JP2021513536A publication Critical patent/JP2021513536A/ja
Publication of JPWO2019154986A5 publication Critical patent/JPWO2019154986A5/ja
Publication of JP2021513536A5 publication Critical patent/JP2021513536A5/ja
Priority to JP2023077703A priority Critical patent/JP2023113648A/ja
Application granted granted Critical
Publication of JP7279054B2 publication Critical patent/JP7279054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020542822A 2018-02-09 2019-02-08 Ｅｄｂ標的化ｉｌ－１２組成物 Active JP7279054B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077703A JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18156141 2018-02-09
EP18156141.6 2018-02-09
EP18179313 2018-06-22
EP18179313.4 2018-06-22
PCT/EP2019/053136 WO2019154986A1 (en) 2018-02-09 2019-02-08 Edb targeting il-12 compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077703A Division JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Publications (4)

Publication Number Publication Date
JP2021513536A JP2021513536A (ja) 2021-05-27
JPWO2019154986A5 JPWO2019154986A5 (https=) 2022-01-31
JP2021513536A5 JP2021513536A5 (https=) 2022-01-31
JP7279054B2 true JP7279054B2 (ja) 2023-05-22

Family

ID=65268973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542822A Active JP7279054B2 (ja) 2018-02-09 2019-02-08 Ｅｄｂ標的化ｉｌ－１２組成物
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Country Status (25)

Country Link
US (1) US12173044B2 (https=)
EP (1) EP3749372B1 (https=)
JP (2) JP7279054B2 (https=)
KR (2) KR102259085B1 (https=)
CN (1) CN111683687B (https=)
AU (2) AU2019219201B2 (https=)
BR (1) BR112020012888A2 (https=)
CA (1) CA3087488C (https=)
CL (1) CL2020002052A1 (https=)
CO (1) CO2020009737A2 (https=)
CR (1) CR20200342A (https=)
CU (1) CU20200054A7 (https=)
EC (1) ECSP20047171A (https=)
ES (1) ES3035714T3 (https=)
IL (1) IL275713A (https=)
JO (1) JOP20200193A1 (https=)
MX (1) MX2020008231A (https=)
MY (1) MY200700A (https=)
PE (1) PE20210122A1 (https=)
PH (1) PH12020551230A1 (https=)
RU (2) RU2758143C1 (https=)
SG (1) SG11202006334XA (https=)
TW (1) TWI844524B (https=)
UY (1) UY38074A (https=)
WO (1) WO2019154986A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230312726A1 (en) * 2020-04-14 2023-10-05 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법
AU2023206004B2 (en) * 2022-01-04 2025-04-17 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523406A (ja) 2000-02-24 2003-08-05 フィロジェン ソチエタ レスポンサビリタ リミテ 病理学的病変における脈管形成の処理のための組成物及び方法
JP2008543278A (ja) 2005-05-11 2008-12-04 フィロゲン エスピーエー フィブロネクチンｅｄ−ｂに対する抗体ｌ１９とインターロイキン１２との融合タンパク質
JP2013502209A (ja) 2009-08-17 2013-01-24 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CN100535013C (zh) 2002-03-11 2009-09-02 菲洛根股份公司 应用抗体分子对肿瘤血管进行选择性定向
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8580267B2 (en) * 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
AU2014257906A1 (en) * 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
SG11201802912PA (en) * 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
WO2018224550A1 (en) * 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523406A (ja) 2000-02-24 2003-08-05 フィロジェン ソチエタ レスポンサビリタ リミテ 病理学的病変における脈管形成の処理のための組成物及び方法
JP2008543278A (ja) 2005-05-11 2008-12-04 フィロゲン エスピーエー フィブロネクチンｅｄ−ｂに対する抗体ｌ１９とインターロイキン１２との融合タンパク質
JP2013502209A (ja) 2009-08-17 2013-01-24 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate

Also Published As

Publication number Publication date
TW201934136A (zh) 2019-09-01
ES3035714T3 (en) 2025-09-08
JP2023113648A (ja) 2023-08-16
EP3749372C0 (en) 2025-04-16
EP3749372B1 (en) 2025-04-16
KR20200109380A (ko) 2020-09-22
CL2020002052A1 (es) 2021-01-04
PE20210122A1 (es) 2021-01-19
IL275713A (en) 2020-08-31
CO2020009737A2 (es) 2020-08-21
AU2019219201A1 (en) 2020-07-23
RU2021130306A (ru) 2021-11-10
MY200700A (en) 2024-01-11
AU2021203986A1 (en) 2021-07-08
CA3087488C (en) 2021-11-02
CR20200342A (es) 2020-10-19
US20200397915A1 (en) 2020-12-24
JOP20200193A1 (ar) 2020-08-06
CN111683687B (zh) 2024-08-02
AU2019219201B2 (en) 2021-07-08
MX2020008231A (es) 2020-09-25
RU2758143C1 (ru) 2021-10-26
CU20200054A7 (es) 2021-05-12
NZ766787A (en) 2024-05-31
UY38074A (es) 2019-10-01
US12173044B2 (en) 2024-12-24
TWI844524B (zh) 2024-06-11
CA3087488A1 (en) 2019-08-15
ECSP20047171A (es) 2020-09-30
PH12020551230A1 (en) 2021-05-17
KR20210063467A (ko) 2021-06-01
CN111683687A (zh) 2020-09-18
WO2019154986A1 (en) 2019-08-15
JP2021513536A (ja) 2021-05-27
KR102259085B1 (ko) 2021-06-03
BR112020012888A2 (pt) 2020-12-08
KR102488801B1 (ko) 2023-01-13
SG11202006334XA (en) 2020-08-28
EP3749372A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
JP7279054B2 (ja) Ｅｄｂ標的化ｉｌ－１２組成物
TWI593707B (zh) Ｃｄ３３抗體類及彼等於治療癌症之用途
JP2023541473A (ja) 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用
CN116261595A (zh) 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途
AU2015249887A1 (en) Novel anti-RNF43 antibodies and methods of use
EP4223777A1 (en) Anti-cd3 antibody and uses thereof
KR20220133884A (ko) 항-mdr1 항체 및 이의 용도
CN113227142A (zh) 抗pd-1抗体及其用途
JP2023527583A (ja) Ｌａｇ３に結合する抗体およびその使用
CN118459588A (zh) 抗c-met抗体
WO2022111476A1 (zh) 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途
KR20240082411A (ko) 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
TW202428608A (zh) 抗b7h3抗體以及其使用方法
EA043910B1 (ru) Иммуноцитокин для нацеленной на злокачественную опухоль доставки il-12 и его применение
WO2025131063A1 (en) Antibody drug conjugates targeting b7-h3 and trop2 and the use thereof
CN120530135A (zh) 抗b7h3抗体和使用方法
JP2026507907A (ja) 抗ｃｔｌａ４抗ｐｄ－１二重特異性抗体を含有する医薬組成物とその使用
WO2023176881A1 (ja) 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
JP2024526221A (ja) 三重特異性抗体、その調製方法および用途
CN121335922A (zh) 抗pd-1/ctla-4/vegf抗体及其用途
CN120322458A (zh) Cd38单克隆抗体及其应用
EA052759B1 (ru) Антитела против pd-l1 и конъюгаты антитело-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230510

R150 Certificate of patent or registration of utility model

Ref document number: 7279054

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250